2006PubMedRequires access

[Preliminary study on effects of sodium ferulate in treating diabetic nephropathy].

Hongwei Chen, Shouli Wang, Xinyi Chen

Open publisher page 4 citations

Abstract

OBJECTIVE: To investigate the effects and mechanisms of sodium ferutate (SF) in treating diabetic nephropathy (DN). METHODS: Eighty patients of diabetes mellitus type 2 with DN were randomly divided into two groups, 40 cases in each group. The routine group treated with conventional treatment including dietary therapy and hypodermic injection of insulin, and the SF group treated with intravenous dripping of SF 300 mg/d additionally besides the conventional therapy, the therapeutic course for both groups was 4 weeks. And 40 healthy volunteers were allocated in a group for normal control. Before and after therapy, levels of fasting blood glucose (FBG), hemoglobin A1c(HbA1c), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), serum creatinine (SCr), blood urea nitrogen (BUN), mean arterial pressure (MAP), urinary albumin excretion rate (UAER), serum collagen type IV (CIV) and endothelin (ET) were detected. RESULTS: After 4 weeks of treatment, FBG and HbA1c reduced obviously in both groups with insignificant difference in comparison of them (P > 0.05). Before treatment, TG, TC, MAP, SCr, BUN, UAER, CIV and ET were markedly higher in DN patients than those in the health control (P < 0.05), these criteria decreased significantly in the SF group (P < 0.05) but insignificantly in the routine group (P > 0.05) after treatment, showing difference between the two groups (P < 0.05). CONCLUSION: Sodium ferulate could ameliorate lipid metabolic disorder, reduce blood pressure, lower UAER and CIV level, and improve renal function in DN patients, the mechanism might be through decreasing ET production and inhibiting the combining of ET with its receptor.

About this research paper

What this paper is about

OBJECTIVE: To investigate the effects and mechanisms of sodium ferutate (SF) in treating diabetic nephropathy (DN). METHODS: Eighty patients of diabetes mellitus type 2 with DN were randomly divided into two groups, 40 cases in each group. The routine group treated with conventional treatment including dietary therapy and hypodermic injection of insulin, and the SF group treated with intravenous dripping of SF 300 mg/d additionally besides the conventional therapy, the therapeutic course for both groups was 4 weeks. And 40 healthy volunteers were allocated in a group for normal control. Before and after therapy, levels of fasting blood glucose (FBG), hemoglobin A1c(HbA1c), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), serum creatinine (SCr), blood urea nitrogen (BUN), mean arterial pressure (MAP), urinary albumin excretion rate (UAER), serum collagen type IV (CIV) and endothelin (ET) were detected. RESULTS: After 4 weeks of treatment, FBG and HbA1c reduced obviously in both groups with insignificant difference in comparison of them (P > 0.05). Before treatment, TG, TC, MAP, SCr, BUN, UAER, CIV and ET were markedly higher in DN patients than those in the health control (P < 0.05), these criteria decreased significantly in the SF group (P < 0.05) but insignificantly in the routine group (P > 0.05) after treatment, showing difference between the two groups (P < 0.05). CONCLUSION: Sodium ferulate could ameliorate lipid metabolic disorder, reduce blood pressure, lower UAER and CIV level, and improve renal function in DN patients, the mechanism might be through decreasing ET production and inhibiting the combining of ET with its receptor.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To investigate the effects and mechanisms of sodium ferutate (SF) in treating diabetic nephropathy (DN). METHODS: Eighty patients of diabetes mellitus type 2 with DN were randomly divided into two groups, 40 cases in each group. The routine group treated with conventional treatment including dietary therapy and hypodermic injection of insulin, and the SF group treated with intravenous dripping of SF 300 mg/d additionally besides the conventional therapy, the therapeutic course for both groups was 4 weeks. And 40 healthy volunteers were allocated in a group for normal control. Before and after therapy, levels of fasting blood glucose (FBG), hemoglobin A1c(HbA1c), triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), serum creatinine (SCr), blood urea nitrogen (BUN), mean arterial pressure (MAP), urinary albumin excretion rate (UAER), serum collagen type IV (CIV) and endothelin (ET) were detected. RESULTS: After 4 weeks of treatment, FBG and HbA1c reduced obviously in both groups with insignificant difference in comparison of them (P > 0.05). Before treatment, TG, TC, MAP, SCr, BUN, UAER, CIV and ET were markedly higher in DN patients than those in the health control (P < 0.05), these criteria decreased significantly in the SF group (P < 0.05) but insignificantly in the routine group (P > 0.05) after treatment, showing difference between the two groups (P < 0.05). CONCLUSION: Sodium ferulate could ameliorate lipid metabolic disorder, reduce blood pressure, lower UAER and CIV level, and improve renal function in DN patients, the mechanism might be through decreasing ET production and inhibiting the combining of ET with its receptor.

Key concepts: Diabetic nephropathy, Internal medicine, Blood urea nitrogen, Medicine, Creatinine, Triglyceride, Endocrinology, Renal function

Related papers

Back to paper searchBrowse research topicsOriginal source
[Preliminary study on effects of sodium ferulate in treating diabetic nephropathy]. — Research Paper | ScholarLens